The FDA says it won’t approve DBV Technologies’ Viaskin Peanut, the novel skin patch allergy desensitization treatment, at least not… Read more »
With much of the Food and Drug Administration’s staff working on the coronavirus pandemic, the timeline for reviews of some… Read more »
New results show that after three years of using the Viaskin Peanut patch in children ages 4 to 11, more… Read more »
DBV Technologies has announced that the FDA has agreed to review the company’s Viaskin Peanut patch for potential regulatory approval.… Read more »
We’re learning more about the two therapies to treat peanut allergies that could soon be available in allergist’s offices in… Read more »
In children, Viaskin Peanut built more allergen tolerance when used over two years.
In trials, Viaskin Peanut allowed some participants to tolerate 10 times more peanut protein than at the outset.